Compare TELA & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | DARE |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 33.4M |
| IPO Year | 2019 | 2014 |
| Metric | TELA | DARE |
|---|---|---|
| Price | $0.71 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.00 | ★ $10.00 |
| AVG Volume (30 Days) | 91.2K | ★ 176.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.59 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $80,275,000.00 | $2,807,885.00 |
| Revenue This Year | $10.23 | $2,115.12 |
| Revenue Next Year | $14.26 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.84 | N/A |
| 52 Week Low | $0.50 | $1.27 |
| 52 Week High | $2.19 | $9.19 |
| Indicator | TELA | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 46.47 |
| Support Level | $0.73 | $1.94 |
| Resistance Level | $0.94 | $2.23 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 26.85 | 55.56 |
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.